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25 Profiling gene expression dynamics underpinning conventional testing 
approaches to better inform pre-clinical evaluation of an age appropriate 
spironolactone formulation.    
Abstract
30 There is a need to accelerate paediatric formulation evaluation and enhance quality of early stage data 
in drug development to alleviate the information pinch point present between formulation 
development and clinical evaluation. This present work reports application of DNA microarrays as a 
high throughput screening tool identifying markers for prediction of bioavailability and formulation 
driven physiological responses. With a focus on enhancing paediatric medicine provision an oral 
35 liquid spironolactone suspension was formulated addressing a paediatric target product profile. Caco-
2 cells cultured on transwell inserts were implemented in transport assays in vitro and DNA 
microarrays were used to examine gene expression modulation. Wistar rats were used to derive in 
vivo bioavailability data. In vitro, genomic and in vivo data sets were concurrently evaluated linking 
drug transport and the genomic fingerprint generated by spironolactone formulation exposure. 
40 Significant changes in gene expression are reported for ABC transporters, SLC transporters, CYP 
enzymes and carboxylesterase enzymes resulting fromas a result of formulation exposure. These 
include genes coding for ATP-binding cassette (ABC) transporters, Solute carrier (SLC) transporters, 
Cytochrome P450 (CYP) enzymes and carboxylesterase enzymes.  Genomic findings better inform 
pre-clinical understanding of pharmacokinetic and pharmacodynamic responses to spironolactone and 
45 its active metabolites than current in vitro drug transport assays alone.
Key Words: - Microarray, Paediatrics, ABC transporters, SLC transporters, CYP enzymes, 
carboxylesterase enzymes.  
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50
1. Introduction 
The lack of suitable formulations in the paediatric patient segment is attributed largely to the 
dynamic physiological state, which is both vastly different to that of adults and changes 
55 significantly with age. As a result, the needs of the paediatric patient segment vary greatly to 
the needs of adults and represent a far more sensitive challenge [1]. Dosage form, route of 
administration, overall dose of active pharmaceutical ingredient (API) and excipients need 
careful consideration when producing an age appropriate dosage form. To aid researchers in 
this area there are a number of regulations and items of legislation in both Europe and the 
60 United States of America designed to promote development in this area and deliver 
appropriate medicines for children. These include the Best Pharmaceuticals for Children Act 
(BPCA) and the Paediatric Equity Act (PREA) in the USA and EU paediatric Regulation; EC 
No. 1901/2006; EC No.1902/2006 in Europe [2,3]. The latter has been in place since 2007 
and applies to both new and off-patent medicinal products. Currently, pharmaceutical 
65 companies seeking marketing authorisation in Europe for products which are covered by 
intellectual property (IP) rights are required to submit a Paediatric Investigation Plan (PIP) to 
the Paediatric committee (PDCO) of the European Medicines Eva uation Agency (EMA). 
The PIP outlines a research plan for investigations in children targeting generation of 
sufficient data to permit marketing authorisation. This includes pre-clinical studies, clinical 
70 studies and quality studies describing formulation development. This is optional for off-
patent products, however engaging with the PIP process when reformulating off-patent 
medicines to provide age appropriate formulations permits applications for paediatric use 
marketing authorisation (PUMA) [3-5]. This carries with it the benefit of 10 years of data 
protection (eight years of data exclusivity and two further years of market protection). 
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75 Despite this incentive there has been poor success rates with only 4 PUMA’s having been 
awarded since the inception of the scheme. This has been attributed to a number of factors, 
which hinder recruitment into clinical trials including current approaches to pre-clinical 
formulation evaluation [6]. 
Specifically, PIP research plans for investigations in children require data from pre-clinical 
80 studies including the prediction of pharmacokinetic responses in vivo. Current practice for 
the assessment of drug permeability includes human colon adenocarcinoma (Caco-2) cells 
cultured on transwell inserts or equivalent as it delivers many elements of the in vivo 
physiological equivalent such as microvilli, enzymatic activity and membrane transporter 
networks [7-9]. The carrier transporters in the intestine have relatively promiscuous 
85 specificity and are involved in the uptake and efflux of range of drug molecules. The genetic 
basis of these biological components and the dynamic nature of such networks means that 
microarray can be deployed for high throughput, cost effective screening to generate enriched 
large-scale data sets describing the physiological system.
This genome wide expression evaluation  allows for a broad, network view of how a given 
90 molecule can impact cellular pathways and their interaction [10-13]. This provides a far more 
complete picture of what is happening in any given system and when combined with open 
access databases such as the Koyoto Encyclopaedia of Genes and Genomes (KEGG or other 
equivalents),  delivers a true and informative systems biology based approach [14].
The aim of the present work was to investigate the application of DNA microarrays to 
95 identify markers suitable for the prediction of intestinal absorption and formulation effect to 
better inform drug development. This was investigated through the evaluation of an oral 
liquid spironolactone suspension which had been formulated in house to address the needs of 
the paediatric patient segment. Caco-2 cells cultured on transwell inserts were used for drug 
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transport assay to model intestinal permeability in vitro and DNA microarrays were 
100 employed to examine gene expression changes occurring during drug transport. Wistar rats 
were used as a rodent model to derive in vivo bioavailability data for comparison. In vitro, 
genomic and in vivo data sets were evaluated to link drug transport and the gene expression 
changes generated by spironolactone as an approach to accelerate formulation evaluation and 
enhance the quality of early stage data generated in the drug development pipeline.
105 Spironolactone is a poorly soluble potassium sparing diuretic which acts as a receptor 
antagonist for the mineralocorticoid aldosterone. It is used clinically in adults for the 
treatment of a number of conditions including heart failure and hypertension [15]. However 
in paediatrics its licensed use is limited to the treatment of oedema in heart failure and in 
ascites, nephrotic syndrome and reduction of hypokalemia induced by diuretics or 
110 amphotericin [16]. Administration is via the oral route with dose regimes ranging from 1-2 
mg/kg daily in 1 to 2 divided doses, up to a maximum of 7 mg/kg daily for neonates. 1-3 
mg/kg daily in 1 to 2 divided doses up to 9 mg/kg for children aged from 1 month to 11 years 
and 50-100 mg daily in 1 to 2 divided doses, up to a maximum of 9 mg/kg daily in children 
aged between 12 – 17 years [16]. Currently, 25, 50 and 100 mg branded (Aldactone®, Pfizer) 
115 tablets and generic equivalents are the only licensed dosage forms. This limits use in 
paediatrics, particularly neonates as solid dosage forms are unsuitable for administration in 
neonates and young children and do not afford the dose flexibility required to effectively 
cover dose requirements in paediatric patients ranging from neonates through to teenagers.
Spironolactone has a solubility of 22 µg/ml in water whereas the desired dosages for a liquid 
120 spironolactone formulation are 10 mg/ml and 5 mg/ml. Therefore, to produce a clinically 
relevant formulation, the solubility of spironolactone would need to be increased 227-fold. 
Additionally, Spironolactone has been shown to be degraded by cyclodextrins meaning that 
this common method of solubilising poorly soluble drugs cannot be used. As such and with 
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an onus on simplicity of formulation and limiting excipient use with paediatric application in 
125 mind, complex methods of solubilising the insoluble drug were rejected in favor of producing 
a suspension.
The aim of the present work was to investigate the application of DNA microarrays to 
identify markers suitable for the prediction of intestinal absorption and formulation effect to 
better inform drug development. This was investigated through the evaluation of an oral 
130 liquid spironolactone suspension which had been formulated in house to address the needs of 
the paediatric patient segment. Caco-2 cells cultured on transwell inserts were used for drug 
transport assay to modelevaluate intestinal permeability in vitro and DNA microarrays were 
employed to examine gene expression changes occurring during drug transport. Wistar rats 
were used as a rodent model to derive in vivo bioavailability data for comparison. In vitro, 
135 genomic and in vivo data sets were evaluated to link drug transport and the gene expression 
changes generated by spironolactone as an approach to accelerate formulation evaluation and 
enhance the quality of early stage data generated in the drug development pipeline.
2. Materials and Methods
140 2.1 Materials
Spironolactone was supplied by Discovery fine chemicals, UK. Xanatural, Pluronic F127, 
Sodium Metabisulphate, Sodium Benzoate and Xylitol were supplied by Sigma Aldrich U.K. 
with the exception of flavour concentrates which were samples provided by Azelis. 
Acetonitrile was supplied by Fisher Scientific U.K. Caco-2 cells (passage 45) were kind gift 
145 from Dr Andrew Collett and Dr Daniel Patten at the University of Huddersfield. 
Polycarbonate transwell permeability supports in 6 well format Permeability supports were 
purchased from Appleton Woods Ltd, U.K. and all tissue culture media components 
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including DMEM, Glutamate, Penstrep, Non-essential amino acids, FBS and HBSS were 
supplied by Sigma Aldrich UK. RNeasy kits for RNA extraction were supplied by Qiagen, 
150 U.K. One-colour microarray-based gene expression analysis low input quick amp labelling 
kit were purchased from Agilent Technologies. Agilent 4 x 44K whole genome arrays were 
used for microarray experimentation (Agilent Technologies, Santa Clara, CA)
2.2 Formulation development
An oral spironolactone suspension suitable for the paediatric patient segment was developed 
155 in house at dosages of 5 mg/ml and 10 mg/ml meeting the following target product profile 
(Table 1). 
Table 1 – Target product profile for spironolactone suspension detailing target 
components for each quality attribute. 
Quality Attribute Target
Route of Administration Oral
Dosage form Acceptable for patients aged from birth to 
<18 years 
Dose Range 1-2mg/kg daily in 1 to 2 divided doses, up 
to a maximum of 7mg/kg daily for neonates. 
1-3mg/kg daily in 1 to 2 divided doses up to 
9mg/kg for children aged from 1 month to 
11 years and 50-100mg daily in 1 to 2 
divided doses, up to a maximum of 9mg/kg 
daily in children aged from 12 – 17 years. 
Includes dose titration.
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Pharmacokinetics Immediate Release
Palatability Neutral/Flavored/Sweetened preferred
Shelf life Minimum of 12 Months
Container closure system Multi-dose
Additional Information All excipients must be acceptable for the 
paediatric patient population
160
2.3 Spironolactone HPLC Method
A Dionex GP50 gradient pump coupled to a Dionex UVD170U detector and a Dionex A550 
auto sampler were combined with a Phenomenex Gemini 5 µm C18 reverse phase HPLC 
column (150 x 4.5 mm with 5 µm Particle Size). Mobile phase was acetonitrile and water 
165 (50:50) and the detection wavelength was set at 254 nm. The injection volume was 50 µl with 
a run time of 12 minutes and retention time of 8 minutes. Preparation of calibration standards 
involved production of six standards via serial dilution in mobile phase. Standards ranged 
from 0.0625 to 0.5 µg/ml and included a blank. Method validation was carried out following 
ICH Guidelines (Q2(R1)) [17]. 
170 2.4 Assessment of Absorption in Vitro
2.4.1 Culture of Caco-2 Cells for permeability assay
Caco-2 cells (passage 48) were seeded at a density of 1.3 x 105 cells/cm2 onto polycarbonate 
transwell permeability supports in 6 well format. Cells were cultured in an incubator (Sanyo) 
at 37 °C in a humidified 5% CO2/95% air atmosphere. Media was changed every 2-3 days 
175 over a three-week period. Trans-epithelial electronic resistance (TEER) measurements were 
taken following each media change and immediately before and after experiments using an 
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EVOM – Epithelial Voltohmmeter (World Precision Instruments Ltd). Monolayer integrity 
was confirmed with TEER values greater than 350 Ωcm2. 
2.4.2 Trans-epithelial flux of spironolactone across Caco-2 monolayers
180 Culture media was removed, and the monolayers washed with HBSS (pH range 6.7 - 7.8) 
before the monolayers were incubated at 37 °C for 30 minutes with 2.5 ml of HBSS 
basolaterally and 1.5 ml apically. In each case, HBSS was then replaced in the apical 
compartment with 1.5 ml of the optimised formulation to be tested. Experiments using cells 
which were not exposed to the drug were used as controls. 200 µl samples were then taken 
185 from the basolateral compartment at time points of 5, 10, 15, 20, 30, 60, 90, and 120 minutes. 
200 µl of HBSS was added in each caseback into each well to maintain volume of solution in 
the basolateral compartment. This was accounted for in calculations. Samples were analysed 
via HPLC. Method validity has been confirmed in line with ICH M9 guidance and all 
experiments were performed in triplicate. The level of transport is described as percentage of 
190 drug arriving in the basolateral compartment, and from this, Papp was calculated.
Following the production of a transport/time graph Papp was calculated using the following 
equation [18];
𝑃𝑎𝑝𝑝 =   ( 𝑉𝑟𝐴𝐶𝑜)(𝑑𝐶𝑑𝑡)
Where;
195 Vr – is the volume of the basolateral chamber (ml)
A – is the filter surface area available for transport (cm2).
C0 – is the initial concentration of drug (mg/µl).
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 - is the initial slope of the cumulative concentration (dC) of drug in the basolateral 
𝑑𝐶
𝑑𝑡
chamber (mg/µl) with time (dt) (s). 
200 2.5 Genomic Evaluation
2.5.1 RNA Extraction 
RNA extraction for Caco-2 was performed using an RNeasy kit (Qiagen) following 
manufacturers guidelines. The extracted RNA was then quantified using a Nanodrop ND-
1000 UV-VIS spectrophotometer (Thermoscientific, Wilmington, DE).
205 2.5.2 Microarray Assay
The microarray assay was performed following the directions for Agilent Technologies’ one-
colour microarray-based gene expression analysis low input quick amp labelling kit. In short, 
1.5 µl of 50 ng total RNA was mixed with 2 µl of spike mix (dilution 4). cDNA master mix 
(Agilent Technologies, Santa Clara, CA) was used to prepare cDNA for all samples ahead of 
210 labelling with cyanine 3-CTP (Cy3) in the labelling reaction. The labelled and amplified 
cRNA was then purified using RNeasy mini spin columns (Qiagen) and quantified using 
Nanodrop ND-1000 UV-VIS spectrophotometer (Thermoscientific, Wilmington, DE). cRNA 
yield and specific activity were calculated.
All samples were then hybridised using Agilent 4 x 44K whole genome arrays for 17 hours at 
215 65 °C in a hybridisation oven (Sheldon manufacturer, Corneilus, OR). Following the 
hybridisation stage slides were washed using the gene expression wash buffer kit (Agilent 
Technologies, Santa Clara, CA) and acetonitrile. 
Slide scanning was carried out using an Agilent Scanner (Agilent Technologies, Santa Clara, 
CA) ran 20-bit scans at a resolution of 50 n. 
220
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2.5.3 Microarray Slide Scanning Validation TIFF Image analysis
Spot centroids located in the corner of each array were used to confirm quality and position. 
Feature extraction software assessed the signal quality of the array determined by the normal 
distribution of the data. The Log values of the processed signal were confirmed to show good 
225 linearity with the Log values of the corresponding concentrations of SpikeIns for all arrays 
used. Median value for the processed signal and the median value for the background 
subtracted signal (mean signal – BG) for the whole array produced in all cases a horizontal 
line with minimal variation. Multiple reference probes across the array confirm 
reproducibility across the length and breadth of the array where a low median coefficient of 
230 variation in the signal level from these probes confirmed. Following TIFF image verification 
following microarray scanning, data normalisation was performed prior to analysis.
2.5.4 Data Processing
Feature Extraction software (V10.7, Santa Clara, CA) was implemented to examine the 
quality of the 16-bit TIFF images obtained by microarray scanning. These images were 
235 assessed on grid alignment, signal quantification and overall slide quality.
2.5.5 Data Clustering and Filtering
Data clustering was performed using TMEV software (version TM4, WA, USA). The 
samples were clustered according to the similarities seen in the gene expression patterns 
using hierarchical clustering algorithm (HCA). The mean values for the level of gene 
240 expression was used to perform comparisons between data sets. For data reduction, TMEV 
was also used to perform principal component analysis (PCA) which was implemented to 
illustrate the main degree of variability in the multidimensional data set. Statistical analysis 
was carried out using significance analysis of microarrays (SAM) to identify statistically 
significant genes which demonstrated either a 2 fold up regulation in expression or a 2 fold 
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245 down regulation in gene expression. Delta values were selected so as that the median false 
discovery rate (FDR) was lower than 2%. These gene lists were then exported to EXCEL 
where the gene tables of SLC and ABC genes were prepared for data entry into KEGG 
http://www.genome.jp/kegg/. Pathway analysis was undertaken using KEGG Pathway and 
Orthology features.  
250 2.6 Assessment of Absorption in Vivo.
All animal experiments complied with the ARRIVE guidelines and experimentation strictly 
adhered to the 1986 Scientific Procedures Act (UK). All protocols have been subject to 
ethical review and were carried out in a designated facility under the project license number 
PPL 30/2743. Male Wistar rats with a body weight of 250g -– 300 g were used. Prepared 
255 formulations were loaded into a 1ml syringe and administered via oral gavage. Dosing was 
calculated depending upon the weight of each individual animal and formulations were 
diluted in H2O, Spironolactone was dosed at 40 mg/kg and 20 mg/kg depending on 
formulation. Following dosing, an additional 1 ml of H2O was administered to rinse in the 
formulations. Blood samples (45 µl) were taken via tail bleeds at 15 minutes, 30 minutes, 45 
260 minutes and, 1 hour, 1.5 hour, 2 hour, 2.5 hour, 3 hour and 4 hour time points. Plasma was 
extracted from blood samples by centrifugation at 2800 x g for 10 minutes. The plasma 
samples were then diluted 1:5 in mobile phase and analysed using HPLC. Test/reverence 
ratios were calculated using data published for spironolactone bioequivalence studies to allow 
for comparison of mean plasma pharmacokinetic parameters without the need to use an 
265 intravenous reference standard.
3. Results and Discussion
3.1 Formulation development and characterisation 
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The first stage of developing an age appropriate formulation of Spironolactone commenced 
with scoping a target product profile comprising of small dose volume, long term stability, 
270 flexibility for dose manipulation and an acceptable formulation presentation. Spironolactone 
is most stable at pH 4.5 [19] and as such the formulation required pH control so as to 
maintain optimum conditions for drug stability and maximize shelf life. Experimental 
investigation into vehicle buffer production revealed that the ratio of 0.1 M citric acid to 0.1 
M trisodium citrate resulted in solvent vehicle with pH 4.5. Following this, Xantural 180 and 
275 Pluronic F127 were selected as viscosity modifier and surfactant respectively and 
investigated across concentration ranges of 0-5% w/v and 0-0.5% w/v respectively in order to 
develop a vehicle offering optimized physical stability to the formulation. Pluronic F127 is 
known to undergo transition from a solution to a gel at the sol-gel transition temperature 
which would be undesirable in this formulation. Although this normally occurs at 
280 concentrations greater than 5% w/v, the effect of Xanatural 180 on this is unknown. All 
concentration of Pluronic and Xanatural were investigated at temperatures up to 55 °C. No 
evidence of Sol-Gel was observed for any of the vehicle compositions tested. Evaluation of 
formulation sedimentation in different concentrations of Pluronic and Xanatural showed that 
inclusion of Pluronic was necessary however increasing the concentration above 1% to 2, 3, 4 
285 or 5% had no impact on rate and volume of sedimentation. Conversely, increasing Xanatural 
180 concentration up to 0.4% gradually reduced the amount of sedimentation until at 0.4% 
w/v, whereby no sedimentation was noticed. Table 2 summarises the final spironolactone 
suspension formulation components.
Table 2 – Oral spironolactone suspension composition – Spironolactone formulations 
290 were produced at doses of 5mg/ml and 10mg/ml.
Spironolactone formulation components
Spironolactone API
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Strawberry Flavour Flavouring agent 
Formulations were assessed for stability at accelerated and long-term conditions for storage 
as set out in the ICH Harmonisation Guidelines (Q1A(R2)) [17]. Over the six month course 
of the stability testing in accelerated conditions withat 40 °C and 75% relative humidity, the 
295 drug content of the formulations remained above 95% of the starting dose indicating that the 
formulations displayed adequate stability in accordance with ICH guidelines and the pH 
remained constant for the duration of the stability testing (Figure 1). Similar results were seen 
for long term conditions, 25 °C and 60% relative humidity, the drug content of all of the 
formulations remained >95% of the starting dose and the pH remained constant for the 
300 duration (Figure 2). The results show formulations were physically and chemically stable 
over 12 months with drug content and pH within acceptable limits.
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10mg/ml Flavoured (Recovery) 5mg/ml Flavoured (Recovery)














Figure 1 - Spironolactone Stability in Accelerated Conditions - Spironolactone recovery 
following HPLC for formulations in accelerated storage conditions is illustrated by the 
305 vertical bars. The drug content of the formulations remained above 95% of the starting dose 
indicating that the formulations display adequate stability in accordance with ICH guidelines. 
Results are generated from triplicate repeats (n=3) and error bars indicate standard deviation 
(RSD). Spironolactone pH stability for formulations in accelerated storage conditions is 
represented by the horizontal lines. For the duration of testing the formulations proved stable 
310 with little variation in pH seen for all samples. Results are generated from triplicate repeats 
(n=3) and error bars indicate standard deviation (RSD).
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Figure 2 – Spironolactone Stability in Long Term Conditions - Spironolactone 
recovery following HPLC for formulations in long term storage conditions is 
315 illustrated by the vertical bars. The drug content of the formulations remained above 
95% of the starting dose indicating that the formulations display adequate stability in 
accordance with ICH guidelines. Results are generated from triplicate repeats (n=3) 
and error bars indicate standard deviation (RSD). Spironolactone pH stability for 
formulations in long term storage conditions is represented by the horizontal lines. For 
320 the duration of testing the formulations proved stable with little variation in pH seen 
for all samples. Results are generated from triplicate repeats (n=3) and error bars 
indicate standard deviation (RSD).
3.2 Assessment of Absorption in Vitro
The next phase of investigation involved, in vitro formulation evaluation (10 mg/ml and 5 
325 mg/ml) using Caco-2 cells for drug transport studies, followed by genome fingerprinting to 
evaluate dynamic gene expression responses to formulation exposure. 
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Caco-2 cells were grown on transwell inserts for a minimum of 21 days to allow for full 
differentiation and monolayer integrity was confirmed through trans-epithelial electrical 
resistance (TEER). This was measured before, during and after permeability experiments. At 
330 appropriate time points during permeability experiments, samples were taken from the 
basolateral chamber and analysed via HPLC. 
The results from transport vs time analysis wereas used to calculate apparent permeability, 
Papp, for both the formulations. The average log value in the current study was -5.81 (Figure 
3). Papp, from previous investigations ranged from 5x10-8 to 5x10-5 [7,12]. The permeability 
335 coefficients for the spironolactone formulations are in keeping with these findings. The 
permeability coefficient or apparent permeability of a molecule (Papp) is considered to be a 
reliable indicator for the expected in vivo drug absorption (Fraction Absorbed (fa)). It is 
generally accepted that completely absorbed drugs have Papp >1x10-6 cm/s. (LogPapp >-6) 
whereas incompletely or poorly absorbed drugs have Papp <1x10-6 cm/s. (LogPapp <-6). 
340







Figure 3 - Apparent permeability of spironolactone in oral liquid suspension 
formulations – Average Log Papp values calculated for spironolactone formulations 
range from -5.96 to -5.70 with an average of -5.81. Results are generated from 
triplicate repeats (n=3) and error bars indicate standard deviation (RSD).
345
  3.3 Genomic Evaluation of Caco-2 cells following drug transport experiments
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Investigation into gene expression changes of Caco-2 cells during drug transport studies were 
intended to identify links between the predicted drug permeability and the expression of the 
genes which code for the intestinal transporters of  spironolactone [20-22]. The aim was to 
350 study the response of transporter super families such as ABC and SLC, cytochrome P450 
(CYP) and carboxylesterase (CES) enzymes. Drug transport studies were carried out using 
transwell arrangements and the genetic profiles of the subsequently harvested Caco-2 cells 
were examined. Cells were harvested at 20 minutes and 60 minutes following initiation of the 
drug transport experiments. The expression patterns for Caco-2 cells in their basal state were 
355 used as a control and compared to cells exposed to the spironolactone formulation. 
Following successful RNA extraction, labelling and amplification, samples were hybridised 
onto microarrays and processed to identify gene expression changes. Data normalisation was 
undertaken before statistical analysis of findings was performed. 
3.3.2 Hierarchical clustering algorithm (HCA)
360 HCA was used to cluster samples into groups based on the similarity in gene expression 
profiles. Control samples were compared to formulation samples at each time point (20, 60 
min) (Figure 4). The HCA clusters showed that gene expression levels in Caco-2 cells which 
had undergone treatment with the drug formulations had been altered from that of the control 
samples where spironolactone formulation was absent. In addition to this, time was indicated 
365 as a factor in the magnitude of this change as greater difference was seen for cell samples 
taken at 60 minutes compared to 20 minutes.
Figure 4 - Hierarchical clustering algorithm (HCA) – Gene expression data for 
control samples was compared to gene expression data for samples exposed to 
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370 formulations at each time point using HCA analysis. Clustering analysis groups 
similar data sets and as shown above, there is significant difference indicated 
between the control gene expression data and the expression data seen at each time 
point. 
375 3.3.3 Principal Component Analysis (PCA)
Eigenvector decomposition (EVD) generated 4 principal components for PCA of samples 
relating to the spironolactone suspension of which 88.9899.99% of the variance was 
described in components 1 and 2 (Table 3). Components 3 and 4 were therefore discounted to 
focus data analysis.
380 Table 3 – Eigenvector decomposition (EVD) - EVD generated 4 principal components for 
PCA of samples relating to the spironolactone suspension.
Eigen Values
Principal Component 1 3.468 63.16%
Principal Component 2 1.419 25.83%
Principal Component 3 0.579 10.55%
Principal Component 4 0.026 0.47%
First 2 components: 88.989 %
First 3 components: 99.534 %
Following HCA, principal component analysis (PCA) plots were generated which showed 
385 that there was a clear difference in the gene expression levels between the control and treated 
samples;  control samples clustered centrally compared to spironolactone formulation at time 
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points 20 minutes and 60 minutes (Figure 5). This difference was seen along component one 
and two of the first and second PCA for the suspension. The differences between the time 
points indicated  greater change in the expression levels  after 60 minutes across the first 
390 component (X-axis) when compared to the change after 20 minutes. This further supports the 
trends identified by HCA analysis.
Figure 5 – First and Second PCA - There is a clear difference in the gene expression levels 
between the control samples and the formuation time points. This is seen along component 
395 one and two. The difference seen bewteen the time points shows a greater change in the gene 
expression after 60 minutes when compared to the change after 20 minutes.
3.3.4 Significance Analysis of Microarrays (SAM)
With definitive differences confirmed for the sample profiles, SAM was carried out on the 
microarray data to identify specific genes which showed a significant change in their level of 
400 expression following transport experiments using spironolactone formulations. Genes with a 
fold difference >2 in the SLC, ABC, CYP and CES families were tabulated and positive or 
negative change in expression indicated. For the spironolactone suspensions, the significant 
gene expression information generated from the SAM analysis is presented in Figure 6. A 
total of 2576 significantly upregulated genes (positive change) and 1235 significantly 
Page 20 of 51
URL: http://mc.manuscriptcentral.com/lpdt; EMAIL: IPHD-peerreview@journals.tandf.co.uk





























































For Peer Review Only
405 downregulated genes (negative change) were identified at a FDR rate of 1.5 % and delta 
value of 0.35. 
SAM Cluster Information - Gene Expression
Figure 6 - SAM Cluster Information - Gene Expression - A total of 2576 upregulated 
(positively significant) genes and 1235 downregulated (negatively significant) genes 
410 were identified, 37282 genes were not significant.
For the spironolactone suspensions there was significant effect on 9 genes in the ABC family, 
71 genes in the SLC family, 51 genes in the CYP family and 5 genes in the CES with a fold 
change >2. In each instance it was interesting to note that all of these genes were up 
415 regulated. Following the production of the SLC, ABC and CYP gene tables the gene names 
were entered into KEGG to identify the pathways affected by the changes in gene expression. 
3.3.5 KEGG Pathway analysis
The genes from the SLC, ABC, CYP and CES gene families for which a significant change in 
gene expression was seen were listed and KEGG pathway identification performed to identify 
420 the role of each (comprehensive gene lists exist as supplementary material). Where no 
pathway information was available genes are omitted from the tables. Pathway information 
was available for 91 of the 136 genes identified. 
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When considering permeability through the intestinal epithelial it is important to consider the 
inherent properties which limit absorption. This includes the physiochemical makeup of the 
425 cell membranes as well as the tight junctions between the cells which are tightly regulated 
and highly selective. For instance, SLC9A3R1 is of interest when examining intestinal 
permeability as it codes for SLC9A3 Regulator 1 (NHERF1). This protein interacts with 
villin and actin which function as linkers between integral membrane and cytoskeletal 
proteins involved with the formation and maintenance of tight junctions [23]. Tight junctions 
430 exist between intestinal enterocytes and are one of the key limiters in modulating paracellular 
intestinal permeability and maintaining membrane barrier function. Although spironolactone 
is not reported to be absorbed paracellularly this may indicate that tight junctions were closed 
in response to exposure to the spironolactone formulation. Evidence of cellular response to 
formulation exposure can also be seen through expression changes in genes involved in 
435 signalling pathways including SLC25A6, SLC3A2, SLC7A5, SLC27A1 and SLC2A2. 
cGMP-PKG signalling has been shown previously to control dynamic responses of tight 
junctions in the blood brain barrier (BBB) through voltage-dependent anion channel protein 1 
which is coded for by SLC25A6 [24]. The tight junctions that form the paracellular barrier at 
the BBB and intestinal enterocytes display remarkable molecular similarities [25]. 
440 Beyond the barrier function of the intestine, efflux transporters and enzymatic activity present 
an additional barrier to drug absorption and their combined action can limit bioavailability 
[26]. Spironolactone has been shown to interact with ABCB1, multidrug resistance protein 1 
(MDR) or P-glycoprotein (P-gp) which is supported by findings of this study with a 8.75 fold 
increase in expression levels [21]. However, this observation suggests  spironolactone co-
445 administration requires clinical monitoring for drugs prone to efflux  which may have 
deleterious clinical impact on their bioavailability [21].   
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Spironolactone is rapidly metabolised following administration via carboxylesterases which 
are known to be expressed in Caco-2 cells and their expression has been shown to be 
upregulated in this investigation with carboxylesterase 1 (hCE-1) showing a 9.26 fold 
450 increase in expression and carboxylesterase 2 (hCE-2) showing a 7.10 fold increase in 
expression [27]. Carboxylesterase metabolism of spironolactone produces a number of active 
metabolites including 7α-thiomethylspironolactone (7α-TMS), 6β-hydroxy-7α-
thiomethylspironolactone (6β-OH-7α-TMS), and canrenone. Of these, 7α-TMS and 6β-OH-
7α-TMS are known to be substrates for CYP3A4 and likely responsible for gene regulation 
455 changes (CYP3A4 is upregulated 7.07 fold). CYP3A4 is the most prominent oxidative CYP 
enzyme present in the human intestine and has been shown to significantly metabolise orally 
administrated drugs and limit bioavailability [28]. 
With a focus on transport mediated absorption and intestinal permeability, there were a large 
proportion of upregulated genes from the SLC superfamily linked to absorption pathways. 
460 SLC1A5, SLC3A2, SLC1A1, SLC3A1, SLC6A19 and SLC7A7 are all active in protein 
absorption while SLC31A1, SLC11A2, SLC26A3, SLC5A6 and SLC6A19 are involved with 
mineral absorption. SLC2A2 and SLC5A6 were similarly identified as being significantly 
upregulated and these are functional in carbohydrate absorption and vitamin absorption 
pathways respectively [14]. Upregulated SLC3A2 codes for the chaperone protein CD98 
465 which can heterodimerize with a number of amino acid transporters including LAT1, LAT2, 
y+LAT1, y+LAT2, and xCT and thereby influence a number of cellular functions including 
transport mechanisms. Of the transporters listed, increases in expression levels were seen for 
LAT1 (SLC7A5) and y+LAT1 (SLC7A7). CD98 dimerises with both, y+LAT1 (SLC7A7) 
can be found in the basolateral border of enterocytes to transfer cationic and large neutral 
470 amino acids from the cell to the extracellular space [29]. LAT1 (SLC7A5) dimerises with 
CD98 to form a functional unit for both the uptake of large neutral amino acids and a number 
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of pharmaceutical drugs. Evidence generated by Amaral and Pinho suggests that tight binding 
of spironolactone to the cytosolic mineralocorticoid receptor in collecting duct principle cells 
drives transcriptional changes, these have been shown to modulate subsequent downstream 
475 changes in LAT1, LAT2 and ASCT2 expression [30]. Our findings indicate that this same 
pathway is also active in intestinal enterocytes and this argument is strengthened as the 
cytosolic mineralocorticoid receptor (NR3C2) for which the expression profile was extracted 
individually was found to be upregulated indicating both that it is present and that capacity 
for activity is increased following exposure of Caco-2 cells to spironolactone formulations 
480 [31]. 
Amino acid transporters have roles beyond drug transport and LAT1 is active in the 
mammalian target of rapamycin (mTOR) signalling pathway. This pathway is activated 
during various cellular processes including tumor formation and angiogenesis, insulin 
resistance, adipogenesis and T-lymphocyte activation and is deregulated in human diseases 
485 such as cancer and type 2 diabetes [14,32]. It is not possible to be definitive given the scope 
of this current study, however modulation of LAT1 gene expression as a result of 
spironolactone formulation exposure may provide early indication of long-term adverse 
effects resulting from mTOR pathway activation. Evidence in support of this is strengthened 
as SLC27A1 and SLC2A2 are seen to be upregulated and code for proteins involved in the 
490 Insulin resistance pathway. Likewise, SLC2A2 and ABCC8 are both upregulated and linked 
to Type II diabetes mellitus. 
3.4 Assessment of Absorption in Vivo.
In vivo drug absorption using rodent models is used routinely in a pre-clinical setting to 
provide the most representative model of pharmacokinetics and pharmacodynamics. Wistar 
495 rats were used in this investigation and spironolactone formulations were loaded into a 1ml 
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syringe prior to administration via oral gavage. Dosing was calculated depending upon the 
weight of each individual animal and blood samples were taken via tail bleeds prior to HPLC 
analysis. The plasma concentration-time profile for the formulations for in vivo absorption is 
shown in figure 7.
500












10mg/ml Spironolactone Flavoured 5mg/ml Spironolactone Flavoured


















Figure 7 – In vivo plasma responses in rats following spironolactone administration 
– Plasma concentrations following oral administration. Results are generated from 
triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
505
The plasma concentration-time profile for all formulations was comparable and 
representative of expected results with TMAX occurring 2.5hours after administration. From 
the plasma concentration-time profile, values for AUC, CMAX and TMAX were determined and 
are shown below in table 4. Values are in keeping with published bioequivalence studies 
510 examining spironolactone formulations [33]. AUC and CMAX are within 5% of published 
values with test/reference (T/R) ratios ranging from 0.91-1.11 with a mean value of 1.02 
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while TMAX was located centrally within 1.5 hours to 4.5 hours. It can therefore be deduced 
that the spironolactone formulations resulted in 80-90% in vivo absorption. 
Table 4 – In vivo results for AUC, CMAX and TMAX – AUC was identified to be 
515 992.80µg*h/mL and 988.97µg*h/mL for the 10mg/ml and 5mg/ml formulations 
respectively. Cmax was shown to range from 363.24µg/ml to 375.37µg/ml and TMAX 








Spironolactone Suspension (10mg/ml) 992.80 375.37 2.5
Spironolactone Suspension (5mg/ml) 988.97 363.24 2.5
Previously reported findings for spironolactone in animal models showed gastrointestinal 
520 absorption estimated to be 82% in rats, 62% in dogs and 103% in monkeys [34]. Our findings 
are in keeping with the values for reported rat models. In comparison, human absorption is 
estimated to be in the range of 70%-90% and a fed state is reported to enhance absorption 
[35]. Following a 100 mg dose administered to human subjects, plasma half-life of 
spironolactone is reported to be 1–2 h with time to CMAX being 2–3.2 h. Maximum blood 
525 concentration is reported as 92–148 ng/mL with area under the concentration–time (0–24 h) 
curve 1430–1541 ng/mL per h and elimination half-life of 18–20 h [36,37]. These values 
represent data as would be expected based on predictions using in vitro and in vivo findings 
of this current study.
4. Conclusions
530 The purpose of this study was to evaluate an oral liquid spironolactone formulation to address 
the current need for an age appropriate oral liquid formulation. Microarray technology has 
been implemented to profile genome dynamics as a response to formulation exposure and 
examine the findings in comparison with conventional in vitro and in vivo screening. 
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Shelf life of 12 months has been confirmed with stability testing following ICH guidelines. In 
535 vitro drug transport studies returned a Log Papp value of -5.81 indicating good in vivo 
absorption. Microarray based gene expression changes provided comprehensive assessment 
of drug-transporter/absorption interaction which in turn could be used as a high throughput 
method to develop generic formulations and with refinement, predict indicative in vivo 
performance of alternative dosage forms. This strategy will allow screening of multiple 
540 variations of formulations and provide sufficient confidence for subsequent pre-clinical and 
clinical testing. 
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Supplement - Fingerprinting genome dynamics for comparison with in 
vitro and in vivo formulation evaluation in the development of age 
appropriate dosage forms – Gene information tables 
 
SLC transporter gene expression response following spironolactone formulation 5 
exposure - Gene identification, expression fold change and pathway identification is 
listed for all genes in the SLC transporter family for which a >2 fold change was seen 
and pathway information was available. 
SLC Transporters 
Transporter Fold Change +ve or -ve KEGG Pathway Identification 
SLC17A9 6.4354215 +ve Linked to Porokeratosis 
SLC1A5 13.079359 +ve 
Protein digestion and absorption pathway, 
Central carbon metabolism in cancer pathway 
SLC25A1 10.693407 +ve 
Linked to Congenital myasthenic syndrome, 
Linked to Combined D-2- and L-2-
hydroxyglutaric aciduria 
SLC25A29 9.254947 +ve Thermogenesis pathway 
SLC25A6 10.979601 +ve 
Calcium signalling pathway, cGMP-PKG 
signalling pathway, Necroptosis pathway, 
Cellular senescence pathway, Parkinson 
disease pathway, Huntington disease pathway, 
Influenza A pathway, Human T-cell leukaemia 
virus 1 infection pathway 
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SLC29A2 15.156823 +ve Alcoholism pathway 
SLC31A1 16.562778 +ve 
Platinum drug resistance pathway, Mineral 
absorption pathway 
SLC38A5 7.1403027 +ve GABAergic synapse pathway 
SLC39A5 7.296592 +ve Linked to Myopia  
SLC3A2 14.07006 +ve 
mTOR signalling pathway, Ferroptosis 
pathway, Protein digestion and absorption 
pathway 
SLC6A8 16.636656 +ve 
Linked to Cerebral creatine deficiency 
syndrome, Linked to X-linked creatine 
deficiency syndrome 
SLC7A5 13.480293 +ve 
mTOR signalling pathway, Central carbon 
metabolism in cancer pathway 
SLC7A8 8.355325 +ve Protein digestion and absorption pathway 
SLC11A2 31.62154 +ve 
Lysosome pathway, Ferroptosis pathway, 
Mineral absorption pathway  
SLC1A1 19.64092 +ve 
Synaptic vesicle cycle pathway, Glutamatergic 
synapse pathway, Protein digestion and 
absorption pathway 
SLC22A5 8.93393 +ve Choline metabolism in cancer pathway 
SLC25A10 17.145796 +ve 
Proximal tubule bicarbonate reclamation 
pathway 
SLC25A13 9.850117 +ve 
Linked to Citrullinemia, Linked to Primary 
hyperammonemic disorders (Urea cycle 
disorders) 
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SLC25A46 10.360896 +ve Linked to Charcot-Marie-Tooth disease 
SLC26A3 9.05577 +ve 
Pancreatic secretion pathway, Mineral 
absorption pathway 
SLC27A1 13.418841 +ve 
PPAR signalling pathway, Insulin resistance 
pathway 
SLC29A3 13.328121 +ve Alcoholism pathway 
SLC2A2 7.823031 +ve 
Insulin secretion pathway, Prolactin 
signalling pathway, Glucagon signalling 
pathway, Type II diabetes mellitus pathway, 
Insulin resistance pathway, Maturity onset 
diabetes of the young pathway, Carbohydrate 
digestion and absorption pathway, Central 
carbon metabolism in cancer pathway. 
Linked to Glycogen storage disease, Linked to 
Fanconi-Bickel syndrome 
SLC35A2 8.219815 +ve 
Linked to Congenital disorders of 
glycosylation type II, Linked to Early infantile 
epileptic encephalopathy 
SLC35C1 20.138887 +ve 
Linked to Leukocyte adhesion deficiency, 
Linked to Congenital disorders of 
glycosylation type II 
SLC38A1 18.407154 +ve 
Glutamatergic synapse pathway, GABAergic 
synapse pathway 
SLC39A13 9.199426 +ve 
Linked to Ehlers-Danlos syndrome, 
spondylodysplastic type 
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SLC39A14 24.078133 +ve Ferroptosis pathway 
SLC3A1 18.950901 +ve Protein digestion and absorption pathway 
SLC44A1 10.62931 +ve Choline metabolism in cancer pathway 
SLC44A2 13.139595 +ve Choline metabolism in cancer pathway 
SLC45A3 6.9271073 +ve 
Transcriptional mis-regulation in cancer 
pathway, MicroRNAs in cancer pathway 
SLC5A6 20.858412 +ve Vitamin digestion and absorption pathway 
SLC6A19 6.3885436 +ve 
Protein digestion and absorption pathway, 
Mineral absorption pathway. Linked to 
Hartnup disorder, Linked to Iminoglycinuria, 
Linked to Hyperglycinuria 
SLC6A4 6.203496 +ve 
Synaptic vesicle cycle pathway, Serotonergic 
synapse pathway. Linked to Obsessive-
compulsive disorder 
SLC7A7 11.712494 +ve 
Protein digestion and absorption pathway. 
Linked to lysinuric protein intolerance, Linked 
to secondary hyperammonemia 
SLC9A3R1 6.900848 +ve 
Tight junction pathway, Parathyroid hormone 
synthesis secretion and action pathway, 
Pathogenic Escherichia coli infection pathway, 
Human papillomavirus infection pathway. 
Linked to Nephrolithiasis/osteoporosis, 
hypophosphatemic 
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ABC transporter gene expression response following spironolactone formulation 10 
exposure - Gene identification, expression fold change and pathway identification is 
listed for all genes in the ABC transporter family for which a >2 fold change was seen 
and pathway information was available. 
ABC Transporters 
Transporter Fold Change +ve or -ve KEGG Pathway Identification 
ABCC8 7.0988774 +ve 
Insulin secretion pathway, Type II diabetes 
mellitus pathway. Linked to permanent 
neonatal diabetes mellitus, linked to transient 
neonatal diabetes mellitus, Linked to familial 
hyperinsulinemic hypoglycemia  
ABCF2 8.409261 +ve Pathogenic Escherichia coli infection pathway 
ABCB1 8.749464 +ve 
ATP-binding cassette, subfamily B 
(MDR/TAP), member 1 
ABCB6 11.907367 +ve 
Linked to hereditary stomatocytosis, linked to 
microphthalmia, Linked to familial 
pseudohyperkalemia 
ABCB7 7.421333 +ve Linked to sideroblastic anaemia 
ABCC3 6.1075015 +ve 
Antifolate resistance pathway, Bile secretion 
pathway 
ABCC5 9.429524 +ve Antifolate resistance pathway 
ABCD4 16.697014 +ve Peroxisome pathway 
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Cytochrome P450 Enzyme gene expression response following spironolactone 15 
formulation exposure - Gene identification, expression fold change and pathway 
identification is listed for all genes in the Cytochrome P450 Enzyme family for which 
a >2 fold change was seen and pathway information was available. 
Cytochrome P450 Enzymes 




KEGG Pathway Identification  
CYP2E1 5.901765057 +ve 
Steroid hormone biosynthesis, Arachidonic acid 
metabolism, Linoleic acid metabolism, Metabolism 
of xenobiotics by cytochrome P450, Drug 
metabolism - cytochrome P450, Drug metabolism - 
other enzymes, Metabolic pathways, Non-alcoholic 
fatty liver disease (NAFLD), Chemical 
carcinogenesis 
CYP2J2 5.749191333 +ve 
Arachidonic acid metabolism, Linoleic acid 
metabolism, Metabolic pathways, Serotonergic 
synapse, Inflammatory mediator regulation of TRP 
channels, Ovarian steroidogenesis 
CYP26B1 4.599662301 +ve Retinol metabolism, Metabolic pathways 
CYP3A7 9.287605916 +ve 
Steroid hormone biosynthesis, Retinol metabolism, 
Metabolic pathways, Chemical carcinogenesis 
CYP11B2 6.987923906 +ve 
Steroid hormone biosynthesis, Metabolic 
pathways, Aldosterone synthesis and secretion 
Page 35 of 51
URL: http://mc.manuscriptcentral.com/lpdt; EMAIL: IPHD-peerreview@journals.tandf.co.uk





























































For Peer Review Only
CYP4F3 4.781126103 +ve Arachidonic acid metabolism, Metabolic pathways 
CYP4V2 6.479034553 +ve 
Familial flecked retina syndrome, Bietti crystalline 
corneoretinal dystrophy 
CYP2C8 5.342657131 +ve 
Arachidonic acid metabolism, Linoleic acid 
metabolism, Retinol metabolism, Drug metabolism 
- cytochrome P450, Metabolic pathways, 
Serotonergic synapse, Chemical carcinogenesis 
CYP1A2 6.028728553 +ve 
Steroid hormone biosynthesis, Caffeine 
metabolism, Tryptophan metabolism, Linoleic acid 
metabolism, Retinol metabolism, Metabolism of 
xenobiotics by cytochrome P450, Drug metabolism 
- cytochrome P450, Metabolic pathways, 
Biosynthesis of secondary metabolites, Chemical 
carcinogenesis 
CYP51A1 6.701533528 +ve Steroid biosynthesis, Metabolic pathways 
CYP1B1 5.581066368 +ve 
Steroid hormone biosynthesis, Tryptophan 
metabolism, Metabolism of xenobiotics by 
cytochrome P450, Ovarian steroidogenesis, 
Chemical carcinogenesis, MicroRNAs in cancer 
CYP27A1 5.154637741 +ve 
Primary bile acid biosynthesis, Metabolic 
pathways, PPAR signalling pathway, Cholesterol 
metabolism 
CYP3A43 6.55835254 +ve Chemical carcinogenesis 
CYP2R1 7.519928796 +ve Steroid biosynthesis, Metabolic pathways 
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CYP24A1 6.882079062 +ve 
Steroid biosynthesis, Metabolic pathways, 
Parathyroid hormone synthesis, secretion and 
action, MicroRNAs in cancer 
CYP2D6 8.501487764 +ve 
Metabolism of xenobiotics by cytochrome P450, 
Drug metabolism - cytochrome P450, Endocrine 
resistance, Serotonergic synapse 
CYP19A1 6.973407083 +ve 
Steroid hormone biosynthesis, Metabolic 
pathways, Ovarian steroidogenesis 
CYP4X1 5.080183496 +ve Serotonergic synapse 
CYP2U1 9.482126701 +ve Arachidonic acid metabolism, Metabolic pathways 
CYP4A11 5.901765057 +ve 
Fatty acid degradation, Arachidonic acid 
metabolism, Retinol metabolism, Metabolic 
pathways, PPAR signalling pathway, Vascular 
smooth muscle contraction, Inflammatory mediator 
regulation of TRP channels 
CYP4F8 6.61709587 +ve Arachidonic acid metabolism, Metabolic pathways 
CYP3A5 5.635286563 +ve 
Steroid hormone biosynthesis, Retinol metabolism, 
Metabolism of xenobiotics by cytochrome P450, 
Drug metabolism - cytochrome P450, Metabolic 
pathways, Chemical carcinogenesis 
CYP2C19 6.42128861 +ve 
Arachidonic acid metabolism, Linoleic acid 
metabolism, Drug metabolism - cytochrome P450, 
Metabolic pathways, Serotonergic synapse, 
Chemical carcinogenesis 
Page 37 of 51
URL: http://mc.manuscriptcentral.com/lpdt; EMAIL: IPHD-peerreview@journals.tandf.co.uk





























































For Peer Review Only
CYP11A1 10.81332671 +ve 
Arachidonic acid metabolism, Linoleic acid 
metabolism, Drug metabolism - cytochrome P450, 
Metabolic pathways, Serotonergic synapse, 
Chemical carcinogenesis 
CYP2F1 14.46130063 +ve 
Steroid hormone biosynthesis, Metabolic 
pathways, Ovarian steroidogenesis, Aldosterone 
synthesis and secretion, Cortisol synthesis and 
secretion, Cushing syndrome 
CYP11B1 12.92451789 +ve 
Steroid hormone biosynthesis, Metabolic 
pathways, Cortisol synthesis and secretion, 
Cushing syndrome 
CYP27B1 5.85475736 +ve 
Steroid biosynthesis, Metabolic pathways, 
Parathyroid hormone synthesis, secretion and 
action, Tuberculosis 
CYP17A1 7.235173816 +ve 
Steroid hormone biosynthesis, Metabolic 
pathways, Ovarian steroidogenesis, Prolactin 
signalling pathway, Cortisol synthesis and 
secretion, Cushing syndrome 
CYP2C9 5.755881365 +ve 
Arachidonic acid metabolism, Linoleic acid 
metabolism, Retinol metabolism, Metabolism of 
xenobiotics by cytochrome P450, Drug metabolism 
- cytochrome P450, Metabolic pathways, 
Serotonergic synapse, Chemical carcinogenesis 
CYP2S1 12.17852083 +ve 
Retinol metabolism, Metabolism of xenobiotics by 
cytochrome P450, Metabolic pathways 
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CYP1A1 11.13978829 +ve 
Steroid hormone biosynthesis, Tryptophan 
metabolism, Retinol metabolism, Metabolism of 
xenobiotics by cytochrome P450, Metabolic 
pathways, Ovarian steroidogenesis, Chemical 
carcinogenesis 
CYP2B6 7.538801038 +ve 
Arachidonic acid metabolism, Retinol metabolism, 
Metabolism of xenobiotics by cytochrome P450, 
Drug metabolism - cytochrome P450, Metabolic 
pathways 
CYP46A1 6.36113458 +ve Primary bile acid biosynthesis 
CYP39A1 10.68083174 +ve Primary bile acid biosynthesis 
CYP7A1 5.342657131 +ve 
Primary bile acid biosynthesis, Steroid hormone 
biosynthesis, Metabolic pathways, PPAR 
signalling pathway, Bile secretion, Cholesterol 
metabolism 
CYP7B1 9.51232016 +ve 
Primary bile acid biosynthesis, Steroid hormone 
biosynthesis 
CYP21A2 9.560005811 +ve 
Steroid hormone biosynthesis, Metabolic 
pathways, Aldosterone synthesis and secretion, 
Cortisol synthesis and secretion, Cushing 
syndrome 
CYP4F2 9.09313066 +ve Arachidonic acid metabolism, Metabolic pathways 
CYP26A1 5.933585535 +ve Retinol metabolism, Metabolic pathways 
CYP2A6 6.028728553 +ve 
Caffeine metabolism, Retinol metabolism, 
Metabolism of xenobiotics by cytochrome P450, 
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Drug metabolism - cytochrome P450, Drug 
metabolism - other enzymes, Metabolic pathways, 
Chemical carcinogenesis 
CYP3A4 7.074985738 +ve 
Steroid hormone biosynthesis, Linoleic acid 
metabolism, Retinol metabolism, Metabolism of 
xenobiotics by cytochrome P450, Drug metabolism 
- cytochrome P450, Drug metabolism - other 
enzymes, Metabolic pathways, Bile secretion, 
Chemical carcinogenesis 
CYP2C18 5.743592511 +ve 
Retinol metabolism, Metabolic pathways, 
Serotonergic synapse, Chemical carcinogenesis 
CYP8B1 5.196221969 +ve 
Primary bile acid biosynthesis, Metabolic 
pathways, PPAR signaling pathway 
CYP2A13 8.771337202 +ve 
Metabolism of xenobiotics by cytochrome P450, 
Chemical carcinogenesis 
 
Carboxylesterase enzyme gene expression response following spironolactone 20 
formulation exposure – Gene identification, expression fold change and pathway 
identification is listed for all genes in the Carboxylesterase enzyme family for which 
a >2 fold change was seen and pathway information was available. 
Carboxylesterase Enzymes 
Enzyme Fold Change +ve or -ve KEGG Pathway Identification 
CES1 9.266629724 +ve Drug metabolism - other enzymes 
CES2 7.103678207 +ve Drug metabolism - other enzymes 
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Figure 1 - Spironolactone Stability in Accelerated Conditions - Spironolactone recovery following HPLC for 
formulations in accelerated storage conditions is illustrated by the vertical bars. The drug content of the 
formulations remained above 95% of the starting dose indicating that the formulations display adequate 
stability in accordance with ICH guidelines. Results are generated from triplicate repeats (n=3) and error 
bars indicate standard deviation (RSD). Spironolactone pH stability for formulations in accelerated storage 
conditions is represented by the horizontal lines. For the duration of testing the formulations proved stable 
with little variation in pH seen for all samples. Results are generated from triplicate repeats (n=3) and error 
bars indicate standard deviation (RSD). 
127x95mm (600 x 600 DPI) 
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Figure 2 – Spironolactone Stability in Long Term Conditions - Spironolactone recovery following HPLC for 
formulations in long term storage conditions is illustrated by the vertical bars. The drug content of the 
formulations remained above 95% of the starting dose indicating that the formulations display adequate 
stability in accordance with ICH guidelines. Results are generated from triplicate repeats (n=3) and error 
bars indicate standard deviation (RSD). Spironolactone pH stability for formulations in long term storage 
conditions is represented by the horizontal lines. For the duration of testing the formulations proved stable 
with little variation in pH seen for all samples. Results are generated from triplicate repeats (n=3) and error 
bars indicate standard deviation (RSD). 
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Figure 3 - Apparent permeability of spironolactone in oral liquid suspension formulations – Average Log Papp 
values calculated for spironolactone formulations range from -5.96 to -5.70 with an average of -5.81. 
Results are generated from triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
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Page 43 of 51
URL: http://mc.manuscriptcentral.com/lpdt; EMAIL: IPHD-peerreview@journals.tandf.co.uk





























































For Peer Review Only
 
Figure 4 - Hierarchical clustering algorithm (HCA) – Gene expression data for control samples was compared 
to gene expression data for samples exposed to formulations at each time point using HCA analysis. 
Clustering analysis groups similar data sets and as shown above, there is significant difference indicated 
between the control gene expression data and the expression data seen at each time point. 
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Figure 5 – First and Second PCA - There is a clear difference in the gene expression levels between the 
control samples and the formuation time points. This is seen along component one and two. The difference 
seen bewteen the time points shows a greater change in the gene expression after 60 minutes when 
compared to the change after 20 minutes. 
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Figure 6 - SAM Cluster Information - Gene Expression - A total of 2576 upregulated (positively significant) 
genes and 1235 downregulated (negatively significant) genes were identified, 37282 genes were not 
significant. 
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Figure 7 – In vivo plasma responses in rats following spironolactone administration – Plasma concentrations 
following oral administration. Results are generated from triplicate repeats (n=3) and error bars indicate 
standard deviation (RSD). 
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Page 47 of 51
URL: http://mc.manuscriptcentral.com/lpdt; EMAIL: IPHD-peerreview@journals.tandf.co.uk





























































For Peer Review Only
Table 1 – Target product profile for spironolactone suspension detailing target components 
for each quality attribute. 
Quality Attribute Target
Route of Administration Oral
Dosage form Acceptable for patients aged from birth to 
<18 years 
Dose Range 1-2 mg/kg daily in 1 to 2 divided doses, up 
to a maximum of 7 mg/kg daily for 
neonates. 1-3 mg/kg daily in 1 to 2 divided 
doses up to 9 mg/kg for children aged from 
1 month to 11 years and 50-100 mg daily in 
1 to 2 divided doses, up to a maximum of 9 
mg/kg daily in children aged from 12 – 17 
years. Includes dose titration.
Pharmacokinetics Immediate Release
Palatability Neutral/Flavored/Sweetened preferred
Shelf life Minimum of 12 Months
Container closure system Multi-dose
Additional Information All excipients must be acceptable for the 
paediatric patient population
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Table 2 – Oral spironolactone suspension composition – Spironolactone formulations were produced 
at doses of 5 mg/ml and 10 mg/ml.
Spironolactone formulation components
Spironolactone API





Strawberry Flavour Flavouring agent 
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Table 3 – Eigenvector decomposition (EVD) - EVD generated 4 principal components for PCA of 
samples relating to the spironolactone suspension.
Eigen Values
Principal Component 1 3.468 63.16%
Principal Component 2 1.419 25.83%
Principal Component 3 0.579 10.55%
Principal Component 4 0.026 0.47%
First 2 components: 88.989 %
First 3 components: 99.534 %
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Table 4 – In vivo results for AUC, CMAX and TMAX – AUC was identified to be 992.80 µg*h/mL and 
988.97 µg*h/mL for the 10 mg/ml and 5 mg/ml formulations respectively. Cmax was shown to range 








Spironolactone Suspension (10 mg/ml) 992.80 375.37 2.5
Spironolactone Suspension (5 mg/ml) 988.97 363.24 2.5
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